Evotec SE Appoints New CEO
Ticker: EVOTF · Form: 6-K · Filed: Apr 23, 2024 · CIK: 1412558
| Field | Detail |
|---|---|
| Company | Evotec Se (EVOTF) |
| Form Type | 6-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, ceo-appointment
TL;DR
Evotec SE gets a new CEO, Dr. Christian Wojczewski, starting July 1st.
AI Summary
Evotec SE announced on April 23, 2024, the appointment of Dr. Christian Wojczewski as its new Chief Executive Officer, effective July 1, 2024. This leadership change is a significant development for the pharmaceutical preparations company.
Why It Matters
The appointment of a new CEO can signal a shift in strategic direction and operational focus for the company, potentially impacting its future performance and partnerships.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty and affect investor confidence.
Key Players & Entities
- Evotec SE (company) — The company making the announcement.
- Dr. Christian Wojczewski (person) — Appointed as the new Chief Executive Officer.
- July 1, 2024 (date) — Effective date of the new CEO's appointment.
- April 23, 2024 (date) — Date of the announcement.
FAQ
Who has been appointed as the new Chief Executive Officer of Evotec SE?
Dr. Christian Wojczewski has been appointed as the new Chief Executive Officer of Evotec SE.
When will the new CEO's appointment be effective?
The appointment of Dr. Christian Wojczewski will be effective July 1, 2024.
What is the name of the company making this announcement?
The company making the announcement is Evotec SE.
On what date was this announcement made?
This announcement was made on April 23, 2024.
What is the primary business of Evotec SE?
Evotec SE is in the business of Pharmaceutical Preparations, SIC code 2834.
Filing Stats: 250 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-04-23 17:13:12
Filing Documents
- evo_6k.htm (6-K) — 11KB
- evo_ex991.htm (EX-99.1) — 3KB
- evo_ex992.htm (EX-99.2) — 2KB
- evo_ex992img1.jpg (GRAPHIC) — 207KB
- evo_ex992img2.jpg (GRAPHIC) — 219KB
- evo_ex992img3.jpg (GRAPHIC) — 131KB
- 0001654954-24-004932.txt ( ) — 785KB
From the Filing
evo_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant's name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F: Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7): On April 23, 2024, Evotec SE (the "Company") announced the appointment of Dr Christian Wojczewski as Chief Executive Officer of the Company, effective 01 July. The ad hoc release is attached hereto as Exhibit 99.1. An accompanying press release is attached hereto as Exhibit 99.2. 2 SIGNATURE Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Evotec SE By: /s/ Laetitia Rouxel Name: Laetitia Rouxel Title: Chief Financial Officer Date: April 23, 2023 3 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Ad hoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 99.2 Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 4